Novo Nordisk (NVO) - A promising milestone that is likely to lead to the rebound of the struggling stock!

I am closely following the developments at Novo Nordisk , after the stock has corrected significantly. The recent approval for Rybelsus in Europe , which positions the medication as the first oral GLP-1 drug with proven cardiovascular benefits, is a significant milestone in my opinion. This solidifies Novo Nordisk's leading role in the diabetes management segment and could pave the way for similar approval in the USA, which would greatly benefit the company. Additionally, the study results regarding the effect of Wegovy on "Food Noise" show that...